CytomX Milestone in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

 - Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -

- Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics -

- CytomX retains option for US co-commercialization and economic rights for certain programs -

https://www.biospace.com/article/cytomx-therapeutics-announces-milestone-achievement-in-probody-t-cell-engaging-bispecific-tcb-collaboration-with-astellas-march-18-2024/